KELOWNA, BC, Feb. 11, 2021 /CNW/ - The Valens Company
Inc. (TSX: VLNS) (OTCQX: VLNCF) (the "Company" or "The Valens
Company"), a leading manufacturer of cannabis derivative
products, today announced the launch of nūance's CBD
100, a high-potency CBD-dominant oil, available in the Medical
Cannabis by Shoppers™ marketplace in the coming weeks. CBD 100
will join nūance's lineup of premium cannabis health and wellness
products developed with trusted ingredients and approachable
formulations that enable both simplified and customized consumer
dosing.
Using Valens' proprietary extraction technology to isolate high
purity cannabidiol (CBD), the carefully curated and naturally
sourced nūance CBD 100 formulation delivers a light and natural
taste by blending MCT oil and flavourless CBD crystalline while
ensuring THC is below detectable levels. The product is packaged in
a 30ml bottle with a drip-controlled dispensing mechanism designed
to allow consumers to personalize their dosage and incorporate the
product into their wellness routine. Two drops of the oil are equal
to approximately 5 mg of CBD, and potency of the product may vary
batch by batch.
The Valens Company previously launched several other nūance
products for Medical Cannabis by Shoppers
patients, including oils and vapes in various blends and
potencies, and expects to unveil additional products in the coming
quarters such as topical formats like bath bombs, body oil,
moisturizer, and relief rub, as well as water drops and additional
premium oils.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis
derivative products with a mission to bring the benefits of
cannabis to the world. The Company provides proprietary cannabis
processing services across five core technologies, in addition to
best-in-class product development, formulation and manufacturing of
cannabis consumer packaged goods. The Valens Company's high-quality
products are exclusively formulated for the medical, therapeutic,
health and wellness, and recreational consumer segments, and are
offered across numerous product formats, including oils, vapes,
concentrates, edibles and topicals, as well as pre-rolls, with a
focus on next-generation product development and innovation. Its
breakthrough patented emulsification technology, SōRSE™ by Valens,
converts cannabis oil into water-soluble emulsions for seamless
integration into a variety of product formats, allowing for
near-perfect dosing, stability, and taste. In partnership with
brand houses, consumer packaged goods companies and licensed
cannabis producers around the globe, the Company continues to grow
its diverse product portfolio in alignment with evolving cannabis
consumer preferences in key markets. Through its wholly owned
subsidiary Valens Labs Ltd., the Company is setting the standard in
cannabis testing and research and development with Canada's only ISO17025 accredited analytical
services lab, named The Centre of Excellence in Plant-Based Science
by partner and scientific world leader Thermo Fisher Scientific.
Discover more on The Valens Company and its subsidiaries at
http://www.thevalenscompany.com.
Notice regarding Forward Looking Statements
All information included in this press release, including any
information as to the future financial or operating performance and
other statements of The Valens Company that express management's
expectations or estimates of future performance, other than
statements of historical fact, constitute forward-looking
information or forward-looking statements within the meaning of
applicable securities laws and are based on expectations, estimates
and projections as of the date hereof. Forward-looking statements
are included for the purpose of providing information about
management's current expectations and plans relating to the future.
Wherever possible, words such as "plans", "expects", "scheduled",
"trends", "indications", "potential", "estimates", "predicts",
"anticipate", "to establish", "believe", "intend", "ability to", or
statements that certain actions, events or results "may", "could",
"would", "might", "will", or are "likely" to be taken, occur or be
achieved, or the negative of these words or other variations
thereof, have been used to identify such forward-looking
information. Specific forward-looking statements include, without
limitation, all disclosure regarding future results of operations,
economic conditions and anticipated courses of action. Investors
and other parties are advised that there is not necessarily any
correlation between the number of SKUs manufactured and shipped and
revenue and profit, and undue reliance should not be placed on such
information.
The risks and uncertainties that may affect forward-looking
statements include, among others, regulatory risk,
United States border crossing and
travel bans, reliance on licenses, expansion of facilities,
competition, dependence on supply of cannabis and reliance on other
key inputs, dependence on senior management and key personnel,
general business risk and liability, regulation of the cannabis
industry, change in laws, regulations and guidelines, compliance
with laws, reliance on a single facility, limited operating
history, vulnerability to rising energy costs, unfavourable
publicity or consumer perception, product liability, risks related
to intellectual property, product recalls, difficulties with
forecasts, management of growth and litigation, many of which are
beyond the control of The Valens Company. For a more comprehensive
discussion of the risks faced by The Valens Company, and which may
cause the actual financial results, performance or achievements of
The Valens Company to be materially different from estimated future
results, performance or achievements expressed or implied by
forward-looking information or forward-looking statements, please
refer to The Valens Company's latest Annual Information Form filed
with Canadian securities regulatory authorities at www.sedar.com or
on The Valens Company's website at www.thevalenscompany.com. The
risks described in such Annual Information Form are hereby
incorporated by reference herein. Although the forward-looking
statements contained herein reflect management's current beliefs
and reasonable assumptions based upon information available to
management as of the date hereof, The Valens Company cannot be
certain that actual results will be consistent with such
forward-looking information. The Valens Company cautions you not to
place undue reliance upon any such forward-looking statements. The
Valens Company disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
applicable law. Nothing herein should be construed as either an
offer to sell or a solicitation to buy or sell securities of The
Valens Company.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-valens-company-adds-cbd-100-to-nance-product-lineup-created-for-medical-cannabis-by-shoppers-inc-301226454.html
SOURCE The Valens Company Inc.